トラベルワクチン市場：タイプ別、疾患別-2025-2030年の世界予測

トラベルワクチン市場は、2023年に82億6,000万米ドルと評価され、2024年には90億9,000万米ドルに達すると予測され、CAGR 10.06%で成長し、2030年には161億8,000万米ドルに達すると予測されています。

トラベルワクチンは旅行用予防接種としても知られ、感染症が流行している地域に旅行する個人の健康安全を確保するために極めて重要です。トラベルワクチンの必要性は、旅行者が黄熱病、A型肝炎、腸チフスなど、特定の地域で流行している病気に感染するのを防ぐ役割に由来します。その用途は、主に国際的な旅行をする個人を対象としており、個人旅行者、ビジネス旅行者、軍人、駐在員などのセグメントで最終用途を見出しています。

同市場の成長に影響を与える重要な要因は、世界化、観光化、事業拡大を背景とした海外渡航頻度の増加です。加えて、健康リスクに対する意識の高まりや保健当局による厳しい規制も市場を前進させています。混合ワクチンのイントロダクションなど、ワクチン開発における技術的進歩は、さらなるビジネスチャンスをもたらしています。企業が利益を得るためには、予防効果が長く持続し、副作用の少ないワクチンの開発に投資することが推奨されます。さらに、旅行用ワクチン情報を発信するためのデジタル・プラットフォームは、市場へのリーチを拡大する可能性があります。

しかし、市場開拓には、新ワクチンの開発コストの高さや、市場参入を遅らせる規制上のハードルといった課題があります。ワクチン接種に対する市民の抵抗や誤った情報も、市場成長の妨げとなる可能性があります。さらに、世界の健康危機の際に見られるようなサプライチェーンの混乱も、入手の妨げになる可能性があります。

技術革新が必要な分野には、新興疾患に対するワクチンの研究開発、旅行者のプロファイルに基づく個別化ワクチンスケジュール、マイクロニードルパッチなどのワクチン送達メカニズムの強化などがあります。市場は地政学的・環境的変化の影響を受けるダイナミックな市場であり、新たな健康脅威に対処するためには、市場関係者の警戒心と適応力が必要となります。こうした課題を効果的に乗り越え、チャンスをつかむためには、市場関係者は保健機関との連携に注力し、市場予測のためにデータ分析を活用し、誤った情報に対抗するための強固なコミュニケーション戦略を維持する必要があります。

市場力学：急速に進化するトラベルワクチン市場の主要市場インサイトを公開

トラベルワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 国際観光の人気の高まり
  • 感染症の流行拡大と混合ワクチンの開発
  • コールドチェーン保管インフラへの最近の投資と改善
• 市場抑制要因
  • 旅行者の認識不足
• 市場機会
  • 新規ワクチン技術の革新と進歩
  • 予防接種とワクチン開発に対する政府・組織の資金援助とイニシアチブ
• 市場の課題
  • ワクチンの取り扱いと保管に関する問題

ポーターのファイブフォーストラベルワクチン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：トラベルワクチン市場における外部からの影響の把握

外部マクロ環境要因は、トラベルワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析トラベルワクチン市場における競合情勢の把握

トラベルワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックストラベルワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、トラベルワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 国際観光の人気の高まり
    • 感染症の蔓延と混合ワクチンの開発
    • コールドチェーン保管インフラへの最近の投資と改善
  • 抑制要因
    • 旅行者の間での認知度が低い
  • 機会
    • 新たなワクチン技術の革新と進歩
    • 予防接種とワクチン開発のための政府および組織の資金援助と取り組み
  • 課題
    • ワクチンの取り扱いと保管に関する問題
• 市場セグメンテーション分析
  • タイプ：免疫反応を誘発するDNAワクチンの進歩
  • 病気：旅行者における肝炎ワクチンの必要性に基づく優先
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 トラベルワクチン市場：タイプ別

• 弱毒化ワクチン
• 結合ワクチン
• DNAワクチン
• 不活性ワクチン
• 組み換えベクターワクチン
• サブユニットワクチン
• トキソイドワクチン

第7章 トラベルワクチン市場：疾患別

• 二酸化ケイ素
• A型肝炎
• B型肝炎
• 日本脳炎
• 麻疹とおたふく風邪
• 髄膜炎菌
• 狂犬病
• 腸チフス
• 水痘
• 黄熱病

第8章 南北アメリカのトラベルワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のトラベルワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのトラベルワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • インド初の国産A型肝炎ワクチンがハイデラバードで発売
  • FDAは、青少年の髄膜炎菌感染症を引き起こす最も一般的な5つの血清群を予防する初の唯一のワクチンであるPENBRAYAを承認しました。
  • ファイザーとビオンテック、2023～2024年COVID-19ワクチンの米国FDA承認を取得

企業一覧

• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Cadila Pharmaceuticals Limited
• Shenzhen Kangtai Biological Products Co., Ltd.
• Novartis AG
• Dynavax Technologies Corporation
• CSL Limited
• Emergent BioSolutions Inc.
• Bio-Med（P）Limited
• Bharat Biotech Ltd.
• Indian Immunologicals Ltd.
• Dano Vaccines & Biologicals Private Limited
• Bavarian Nordic A/S
• Johnson & Johnson Services, Inc
• Pfizer Inc.
• Incepta Pharmaceuticals Ltd.
• GlaxoSmithKline PLC
• Serum Institute of India Pvt. Ltd.
• Abbott Laboratories
• AstraZeneca PLC
• Walvax Biotechnology Co., Ltd.
• Bio-Manguinhos
• Valneva SE
• Sanofi S.A.
• Biological E Limited

LIST OF FIGURES

• FIGURE 1. TRAVEL VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. TRAVEL VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TRAVEL VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. TRAVEL VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INACTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RECOMBINANT VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DPT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY JAPANESE ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MEASLES AND MUMPS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 45. CHINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 47. INDIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. INDIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 51. JAPAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 53. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 55. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 57. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 59. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 61. TAIWAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. TAIWAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 63. THAILAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. THAILAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 65. VIETNAM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. VIETNAM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 67. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 69. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 70. DENMARK TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. DENMARK TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 72. EGYPT TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. EGYPT TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 74. FINLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. FINLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 76. FRANCE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. FRANCE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 78. GERMANY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. GERMANY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 80. ISRAEL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. ISRAEL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 82. ITALY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. ITALY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 84. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 86. NIGERIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. NIGERIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 88. NORWAY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. NORWAY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 90. POLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. POLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 92. QATAR TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. QATAR TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 94. RUSSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. RUSSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 96. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 98. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 100. SPAIN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. SPAIN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 102. SWEDEN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SWEDEN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 104. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 106. TURKEY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. TURKEY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 108. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 110. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 112. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 113. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

The Travel Vaccines Market was valued at USD 8.26 billion in 2023, expected to reach USD 9.09 billion in 2024, and is projected to grow at a CAGR of 10.06%, to USD 16.18 billion by 2030.

Travel vaccines, also known as travel immunizations, are crucial for ensuring the health safety of individuals traveling to regions with prevalent infectious diseases. The necessity of travel vaccines stems from their role in preventing travelers from contracting diseases such as yellow fever, hepatitis A, and typhoid, which are prevalent in certain geographical areas. Their application is primarily focused on individuals who travel internationally, and they find end-use across segments such as individual tourists, business travelers, military personnel, and expatriates.

A significant factor influencing the growth of this market is the increasing international travel frequency, driven by globalization, tourism, and business expansion. Additionally, heightened awareness of health risks and stringent regulations by health authorities also propel the market forward. Technological advancements in vaccine development, such as the introduction of combination vaccines, present further opportunities. For businesses to capitalize, investing in the development of vaccines with longer-lasting protection and fewer side effects is recommended. Moreover, digital platforms for disseminating travel vaccine information can expand market reach.

However, the market is faced with challenges, such as the high cost of developing new vaccines and regulatory hurdles that can delay market entry. Public resistance to vaccination and misinformation can also hinder market growth. Furthermore, supply chain disruptions, as observed during global health crises, can impede availability.

Areas ripe for innovation include the research and development of vaccines against emerging diseases, personalized vaccine schedules based on traveler profiles, and enhanced vaccine delivery mechanisms, such as micro-needle patches. The market is dynamic, influenced by geopolitical and environmental changes, which necessitate vigilance and adaptability from market players to address emerging health threats. To effectively navigate these challenges and seize opportunities, market players must focus on collaboration with health organizations, leverage data analytics for market forecasting, and maintain robust communication strategies to counter misinformation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Travel Vaccines Market

The Travel Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Popularity of International Tourism
  • Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
  • Recent Investments and Improvement in Cold Chain Storage Infrastructure
• Market Restraints
  • Limited Awareness Amongst Travelers
• Market Opportunities
  • Innovations in Novel Vaccine Technologies and Advancements
  • Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
• Market Challenges
  • Issues Related to Vaccine Handling and Storage

Porter's Five Forces: A Strategic Tool for Navigating the Travel Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Travel Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Travel Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Travel Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Travel Vaccines Market

A detailed market share analysis in the Travel Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Travel Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Travel Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Travel Vaccines Market, highlighting leading vendors and their innovative profiles. These include Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Cadila Pharmaceuticals Limited, Shenzhen Kangtai Biological Products Co., Ltd., Novartis AG, Dynavax Technologies Corporation, CSL Limited, Emergent BioSolutions Inc., Bio-Med (P) Limited, Bharat Biotech Ltd., Indian Immunologicals Ltd., Dano Vaccines & Biologicals Private Limited, Bavarian Nordic A/S, Johnson & Johnson Services, Inc, Pfizer Inc., Incepta Pharmaceuticals Ltd., GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Abbott Laboratories, AstraZeneca PLC, Walvax Biotechnology Co., Ltd., Bio-Manguinhos, Valneva SE, Sanofi S.A., and Biological E Limited.

Market Segmentation & Coverage

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines, Inactive Vaccines, Recombinant Vector Vaccines, Subunit Vaccines, and Toxoid Vaccines.
• Based on Disease, market is studied across DPT, Hepatitis A, Hepatitis B, Japanese Encephalitis, Measles and Mumps, Meningococcal, Rabies, Typhoid, Varicella, and Yellow Fever.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Popularity of International Tourism
    • 5.1.1.2. Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
    • 5.1.1.3. Recent Investments and Improvement in Cold Chain Storage Infrastructure
  • 5.1.2. Restraints
    • 5.1.2.1. Limited Awareness Amongst Travelers
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovations in Novel Vaccine Technologies and Advancements
    • 5.1.3.2. Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
  • 5.1.4. Challenges
    • 5.1.4.1. Issues Related to Vaccine Handling and Storage
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Advancements in DNA vaccines to induce immune response
  • 5.2.2. Disease: Need based preference for hepatitis vaccines among travelers
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Travel Vaccines Market, by Type

• 6.1. Introduction
• 6.2. Attenuated Vaccines
• 6.3. Conjugate Vaccines
• 6.4. DNA Vaccines
• 6.5. Inactive Vaccines
• 6.6. Recombinant Vector Vaccines
• 6.7. Subunit Vaccines
• 6.8. Toxoid Vaccines

7. Travel Vaccines Market, by Disease

• 7.1. Introduction
• 7.2. DPT
• 7.3. Hepatitis A
• 7.4. Hepatitis B
• 7.5. Japanese Encephalitis
• 7.6. Measles and Mumps
• 7.7. Meningococcal
• 7.8. Rabies
• 7.9. Typhoid
• 7.10. Varicella
• 7.11. Yellow Fever

8. Americas Travel Vaccines Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Travel Vaccines Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Travel Vaccines Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad
  • 11.3.2. FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
  • 11.3.3. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Companies Mentioned

• 1. Merck & Co., Inc.
• 2. Takeda Pharmaceutical Company Limited
• 3. Cadila Pharmaceuticals Limited
• 4. Shenzhen Kangtai Biological Products Co., Ltd.
• 5. Novartis AG
• 6. Dynavax Technologies Corporation
• 7. CSL Limited
• 8. Emergent BioSolutions Inc.
• 9. Bio-Med (P) Limited
• 10. Bharat Biotech Ltd.
• 11. Indian Immunologicals Ltd.
• 12. Dano Vaccines & Biologicals Private Limited
• 13. Bavarian Nordic A/S
• 14. Johnson & Johnson Services, Inc
• 15. Pfizer Inc.
• 16. Incepta Pharmaceuticals Ltd.
• 17. GlaxoSmithKline PLC
• 18. Serum Institute of India Pvt. Ltd.
• 19. Abbott Laboratories
• 20. AstraZeneca PLC
• 21. Walvax Biotechnology Co., Ltd.
• 22. Bio-Manguinhos
• 23. Valneva SE
• 24. Sanofi S.A.
• 25. Biological E Limited